Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Completed · Phase 1

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with moderate hepatic impairment and in matched healthy participants.

Key facts

Study ID

NCT05437120

Run by

Vertex Pharmaceuticals Incorporated

People needed

16

Starts

2022-07-22

Expected to finish

2023-03-16

Last updated by the study team

2023-03-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

Where it is running

• Clinical Pharmacology of Miami, LLC — Miami, Florida, United States
• GCP Research — St. Petersburg, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.